cisplatin + 5-fluorouracil (5FU)

DRUG2 trials

Conditions

Carcinoma, Pancreatic DuctalCarcinoma, Squamous Cell of Head and NeckEsophageal Squamous Cell CarcinomaEsophagogastric Junction NeoplasmsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsRecurrent Head and Neck Squamous Cell Carcinoma

Phase 1

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

CompletedNCT02658214

AstraZenecaCarcinoma, Pancreatic Ductal, Carcinoma, Squamous Cell of Head and Neck, Esophageal Squamous Cell Carcinoma +7

Start: 2016-04-28End: 2019-11-14Updated: 2020-08-20

Phase 3

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

RecruitingNCT07026474

Universität des SaarlandesRecurrent Head and Neck Squamous Cell Carcinoma

Start: 2025-10-30End: 2032-12-31Target: 214Updated: 2026-03-02

Cancer Medicine2023-07-255 citations

Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).

Journal of Clinical Oncology2019-01-299 citations

cisplatin + 5-fluorouracil (5FU)

Sponsors

Conditions

Phase 1

Phase 3

Related Papers